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Low millimolar concentrations of ascorbate are capable of inflicting lethal damage on a high
proportion of cancer cells lines, yet leave non-transformed cell lines unscathed. Extracellu-
lar generation of hydrogen peroxide, reflecting reduction of molecular oxygen by ascorbate,
has been shown to mediate this effect. Although some cancer cell lines express low cata-
lase activity, this cannot fully explain the selective sensitivity of cancer cells to hydrogen
peroxide. Ranzato and colleagues have presented evidence for a plausible new explana-
tion of this sensitivity – a high proportion of cancers, via NADPH oxidase complexes or
dysfunctional mitochondria, produce elevated amounts of superoxide.This superoxide, via
a transition metal-catalyzed transfer of an electron to the hydrogen peroxide produced by
ascorbate, can generate deadly hydroxyl radical (Haber–Weiss reaction). It thus can be pre-
dicted that concurrent measures which somewhat selectively boost superoxide production
in cancers will enhance their sensitivity to i.v. ascorbate therapy. One way to achieve this
is to increase the provision of substrate to cancer mitochondria. Measures which inhibit
the constitutive hypoxia-inducible factor-1 (HIF-1) activity in cancers (such as salsalate and
mTORC1 inhibitors, or an improvement of tumor oxygenation), or that inhibit the HIF-1-
inducible pyruvate dehydrogenase kinase (such as dichloroacetate), can be expected to
increase pyruvate oxidation. A ketogenic diet should provide more lipid substrate for tumor
mitochondria.The cancer-killing activity of 42°C hyperthermia is to some degree contingent
on an increase in oxidative stress, likely of mitochondrial origin; reports that hydrogen per-
oxide synergizes with hyperthermia in killing cancer cells suggest that hyperthermia and
i.v. ascorbate could potentiate each other’s efficacy. A concurrent enhancement of tumor
oxygenation might improve results by decreasing HIF-1 activity while increasing the inter-
action of ascorbic acid with oxygen. An increased pool of labile iron in cancer cells may
contribute to the selective susceptibility of many cancers to i.v. ascorbate; antagonism of
NF-kappaB activity with salicylate, and intravenous iron administration, could be employed
to further elevate free iron in cancers.
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INCREASED SUPEROXIDE PRODUCTION MAY RATIONALIZE
SELECTIVE SENSITIVITY OF CANCERS TO ASCORBATE
Low millimolar concentrations of ascorbate – achievable clinically
by intravenous high-dose administration, but not oral adminis-
tration (1, 2) – are capable of killing many cancer cell lines in vitro,
whereas, non-malignant cell lines are not harmed by ascorbate in
concentrations as high as 20 mM (3, 4). In mice bearing trans-
planted tumors, parenteral administration of high-dose ascor-
bate has been reported to slow cancer growth, and to potentiate
response to concurrent gemcitabine (2, 5, 6).
Extracellular catalase, but not superoxide dismutase, abolishes
the toxicity of extracellular ascorbate to cancer cells (3). Levine
and colleagues have shown that, in vivo, millimolar levels of
ascorbate generate superoxide, hydrogen peroxide, and ascorbyl
radical in the extracellular space; it is suspected that transition
metals bound to proteins in the extracellular space catalyze trans-
fer an electron from ascorbate to molecular oxygen, producing
superoxide that is then dismutated to yield hydrogen peroxide.
Since superoxide does not readily transit cell membranes, and
since extracellular catalase abolishes ascorbate’s toxicity to can-
cer cells, hydrogen peroxide appears to mediate, in whole or
in part, this toxicity. Indeed, Levine’s group has shown that
micromolar concentrations of hydrogen peroxide that realistically
could be generated by ascorbate kill an ascorbate-sensitive lym-
phoma cell line in a manner identical to that seen with ascorbate
exposure (3). These researchers also demonstrated that expo-
sure of cancer cell lines to dehydroascorbate, in amounts which
boosted intracellular ascorbate levels to the same level achieved
by extracellular ascorbate exposure, was not toxic to cancer cells;
hence, extracellular effects of ascorbate are key to ascorbate’s
cytotoxicity (3).
It clearly is of interest to clarify the molecular basis of extracel-
lular ascorbate’s selective toxicity to many cancer cell lines. It has
been suggested that the failure of ascorbate to kill non-malignant
cells may reflect the superior capacity of these cells to dispose of
hydrogen peroxide via catalase or glutathione peroxidase activity.
www.frontiersin.org September 2014 | Volume 4 | Article 249 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McCarty and Contreras Superoxide and ascorbate therapy
Indeed, there are a number of reports of low catalase activity in
various cancer cell lines (7).
However, cancer cells are not always inherently deficient in these
activities, and Ranzato et al. reported that, although a malignant
mesothelioma cell line was much more sensitive to the lethality
of extracellular ascorbate than were normal mesothelial cells, the
latter cell line actually had less catalase activity than the mesothe-
lioma (8). These researchers then discovered that the mesothe-
lioma cells were generating more superoxide than the normal
mesothelial cells – via Nox4 activity, as well as mitochondrial activ-
ity – and that measures which suppressed superoxide production
in the mesothelioma (apocynin, rotenone, and Nox4 anti-sense)
all markedly protected the cancer cells from ascorbate exposure.
They therefore postulated that a Haber–Weiss reaction, in which
extracellularly generated hydrogen peroxide was interacting with
superoxide produced within the cancer cells to generate vicious
hydroxyl radicals, was a key mediator of the lethal impact of ascor-
bate exposure on cancer cells. This model is consistent with a
previous report that pretreatment of cancer cells with the cell-
permeant iron chelator deferoxamine – but not cell-impermeant
iron chelators – protected these cells from subsequent ascorbate
exposure (6); iron is of course a catalyst for the Haber–Weiss reac-
tion. The selective sensitivity of many cancer cell lines to killing
by ascorbate may therefore reflect, to a large degree, the tendency
of cancers to generate superoxide at an increased rate – comple-
mented in some but not all cases by a deficiency of superoxide
dismutase and/or peroxidase activities.
Spitz and colleagues have confirmed that superoxide produc-
tion is increased in a number of cancer cell lines, and demonstrate
that much of this superoxide is of mitochondrial origin (9). When
cancer cells as well as non-malignant cell lines were exposed to
the mitochondrial respiratory inhibitor antimycin, the increase in
superoxide production was markedly higher in the cancer cells.
This suggests that the mitochondria of cancer cells tend to have
dysfunctional respiratory chains, such that a higher proportion of
the electrons flowing down these chains are diverted to superoxide
production at complexes I, II, and III. Indeed, there are a number
of reports that the mitochondria of cancer cells are structurally
abnormal, and that mutations of mitochondrial DNA are more
common in cancer (10–13). Such mutations might be expected
to impair the functional efficiency of respiratory chains. There
is recent evidence that mitochondrial superoxide production is
notably high in melanomas that have developed resistance to the
BRAF inhibitor vemurafenib (14); hence, such cancers may be
good candidates for i.v. ascorbate therapy.
A corollary of these considerations is that an increase in sub-
strate delivery to cancer mitochondria would be expected to
boost superoxide production – and hence sensitize cancer cells
to concurrent sodium ascorbate therapy.
A parallel line of research has demonstrated that superoxide
production by NADPH oxidase complexes is elevated in a high
proportion of cancer cell lines (7, 15). It appears that NADPH
oxidase activation and dysfunctional mitochondria collaborate to
increase superoxide production in a high proportion of cancers.
Arguably, this phenomenon may contribute to the selective sensi-
tivity of malignant cell lines to high concentrations of extracellular
ascorbate in vitro. Whether Nox2 activity in the plasma membrane
is of importance in this regard might be questioned, as this gener-
ates superoxide extracellularly. (The possibility that extracellular
production of hydroxyl radical in the microenvironment of Nox2
complexes might induce membrane damage might however be
entertained.) However, other forms of Nox are expressed intra-
cellularly, and Nox4 is often found in association with nuclear
membranes, where it can promote oxidative damage to DNA
(16, 17). As noted, both apocynin and Nox4 anti-sense treat-
ment markedly alleviated the toxicity of extracellular ascorbate
to mesothelioma cells (8).
Since superoxide does not readily traverse membranes, the sub-
cellular compartment in which superoxide is generated should
determine the site of hydroxyl radical generation when cancer
cells are exposed to extracellular ascorbate. The fact that ascorbate-
mediated cell death shows features of both necrosis and apoptosis
suggests that damage to DNA is not the sole mediator of this
toxicity, though it might play a role in this regard (3).
A moderate increase in superoxide production within cancers
may in fact be selected for, as an increase in hydrogen peroxide
level can reversibly inhibit tyrosine phosphatase activities that tar-
get tyrosine kinases promoting cancer malignancy and survival
(18, 19). Hydrogen peroxide can also boost the activity of another
pro-malignancy factor, hypoxia-inducible factor-1 (HIF-1), by
oxidizing intracellular ascorbate and thereby inhibiting proline
and asparagyl hydroxylases that target it for proteasomal degra-
dation and inhibit the function of its transactivational domain
(20–24). And activation of NF-kappaB, a mediator of aggressive
behavior and chemoresistance in many cancers, can also be up-
regulated by hydrogen peroxide (25). Moreover, oxidative stress
in cancers or pre-neoplastic tissues promotes the genetic lability
that promotes cancer induction, progression, and chemoresistance
(26). The relative deficit of catalase activity in some cancers – which
presumably renders the hydrogen peroxide generated during i.v.
ascorbate therapy more effective – likewise may be selected for.
The high constitutive activity of HIF-1 in many aggressive can-
cers – reflecting tumor hypoxia as well as increases in growth
factor and NF-kappaB signaling (27) – is now believed to be a
key mediator of the “Warburg effect,” wherein cancers are char-
acterized by an up-regulation of aerobic glycolysis and decrease
in mitochondrial respiratory activity (28, 29). This increase in
HIF-1 activity works to lessen oxidative stress in tumors in various
ways. It does so in part via induction of pyruvate dehydrogenase
kinase (PDK), an inhibitor of the pyruvate dehydrogenase complex
(30–32). When pyruvate dehydrogenase is inhibited, glycolytically
generated pyruvate is more likely to be converted to lactate and
secreted, than it is to serve as substrate for mitochondrial oxida-
tion. As a result,mitochondrial superoxide generation is decreased.
Moreover, HIF-1’s inductive effect on glucose transporters, as well
as key enzymes of the glycolytic pathway and hexose phosphate
shunt, provides antioxidant protection to cancers (33). The hex-
ose phosphate shunt generates the NADPH needed to maintain
glutathione in its reduced configuration; reduced glutathione is
of crucial importance to the antioxidant defenses of cells. And
the pyruvate generated by glycolysis can directly quench perox-
ides (34, 35). [Conversely, glucose deprivation or 2-deoxyglucose
administration can impair cancer’s antioxidant defenses (33)].
Hence, HIF-1 activity tends to decrease superoxide production
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while boosting the antioxidant defenses of cancer cells. Recently,
Sinnberg and colleagues have demonstrated that exposure of can-
cer cells lines to the HIF-1 activator cobalt, or to severe hypoxia,
can greatly lessen the sensitivity of cancer cells lines to killing
by extracellular ascorbate (36). They propose that this phenome-
non may explain why published clinical trials with i.v. ascorbate
therapy have failed to report objective responses, in sharp contrast
to the lethal impact of low millimolar ascorbate on cancer cell lines
in vitro. Of course, severe hypoxia could also be expected to lessen
ascorbate’s ability to generate extracellular superoxide (7).
INCREASING SUBSTRATE DELIVERY TO CANCER
MITOCHONDRIA – DICHLOROACETATE AND KETOSIS
It follows that strategies that suppress HIF-1 activity in cancers
would likely be useful as adjuvants to i.v. ascorbate therapy – pro-
vided that these strategies do not hinge on boosting antioxidant
activity in the tumor. mTORC1 inhibitors (e.g., rapalogs and
metformin), salicylate, and high-dose alpha-ketoglutarate may
have some utility in this regard, as reviewed recently (27). A
particularly interesting and quite feasible option would be to
administer dichloroacetate (DCA), a PDK inhibitor, which disin-
hibits pyruvate dehydrogenase activity. By routing more pyruvate
to mitochondrial oxidation, DCA could be expected to enhance
mitochondrial superoxide production, while decreasing the pool
of pyruvate that functions as a direct oxidant scavenger (37–40).
Indeed, Kluza and colleagues have recently reported that DCA
increases mitochondrial superoxide production in a melanoma
cell line, and potentiates the cytotoxic activity of elesclomol, a
drug-in-development, which acts on mitochondria to potenti-
ate their superoxide production (41). DCA has the particular
merit that it can be expected to increase mitochondrial substrate
availability more notably in cancer cells characterized by HIF-1
activation (i.e., which express the Warburg phenotype) than in
most healthy cells, owing to the fact that such cancer cells tend
to have much higher PDK activity than normal cells. DCA has
the potential to decrease HIF-1 activity by breaking a positive
feedback loop whereby the build-up of glycolytic intermediates
secondary to pyruvate dehydrogenase inhibition stabilizes HIF-1
(42). It should be noted that oral DCA in amounts sufficient to
inhibit PDK activity in vivo is well tolerated, aside from mild dis-
tal paresthesias seen in a minority of patients during prolonged
treatment (43, 44); hence, it likely would be well tolerated if given
episodically in conjunction with i.v. ascorbate therapy.
An alternative means of boosting substrate delivery to cancer
mitochondria – while modestly lessening the ability of glucose
to provide antioxidant protection to cancers – is to feed a keto-
genic diet. In mice bearing human lung cancer xenografts, a
ketogenic diet has been shown to increase oxidative stress within
the tumors, and sensitize these tumors to concurrent radiother-
apy (45). Evidently, under ketotic conditions, cancers will derive
a higher proportion of their ATP from the oxidation of free fatty
acids and ketone bodies, which are mitochondrial substrates.
COPING WITH TUMOR HYPOXIA
This strategy of amplifying mitochondrial activity within cancers
as an adjuvant to i.v. ascorbate has a potential drawback – by
increasing tumor oxygen consumption, it could be expected to
amplify tumor hypoxia. Indeed, Zwicker et al. report that, whereas,
DCA enhances the radiosensitivity of human cancer cell lines
in vitro, it actually lessens their radiosensitivity in vivo, appar-
ently because DCA treatment enhances tumor hypoxia (46). Since
intense hypoxia could be expected to compromise ascorbate’s abil-
ity to generate superoxide, it is conceivable that this phenomenon
would be pertinent to i.v. ascorbate therapy. Conversely, measures
which boost tumor oxygen levels may have potential for increas-
ing the efficacy of such therapy (36). Infusion of perfluorochemical
oxygen carriers – used safely as “artificial blood” – has the ability
to alleviate tumor hypoxia to some degree. The perfluorochemical
agent perftoran, approved for clinical use in Russia and Mexico,
has been employed at Oasis of Hope Hospital as an adjuvant to its
i.v. ascorbate cancer protocol (47). Hyperbaric oxygen, which can
be employed as a radiosensitizer, might also be worth exploring in
the context of ascorbate therapy (48, 49).
HYPERTHERMIA BOOSTS SUPEROXIDE PRODUCTION IN
CANCERS
An additional strategy for boosting superoxide production within
cancer cells is hyperthermia. A number of studies have reported
that cancer cells incubated at 42–43°C experience increased oxida-
tive stress, and that antioxidant measures render this heat stress less
cytocidal (50–54). Notably, transfection of cancer cells with the
mitochondrial superoxide dismutase markedly lessens their sensi-
tivity to heat killing (53, 55). This strongly suggests that increased
mitochondrial generation of superoxide is largely responsible for
the oxidative stress imposed by hyperthermia on cancer cells.
Conceivably, the somewhat selective toxicity of hyperthermia
to cancer cells may reflect their tendency to express dysfunc-
tional mitochondria with an increased propensity to generate
superoxide.
Of particular interest is a study showing that heat increases
the cytotoxicity of hydrogen peroxide to Chinese hamster ovary
cells (56). Moreover, in nude mice peritoneally seeded with a
human colorectal cancer, hyperthermic intraperitoneal perfusion
slowed the growth of the cancer, and co-infusion of tolerable lev-
els of hydrogen peroxide greatly amplified the response seen with
hyperthermia alone (57). Since i.v. ascorbate therapy works by
generating hydrogen peroxide within the extracellular space of
tumors, these findings predict that concurrent hyperthermia treat-
ment (achieving temperatures at or near 42°C) should potentiate
the therapeutic response to i.v. ascorbate – or vice versa.
MITOCHONDRIAL TOXINS
Several agents, including the investigational drug elesclomol and
aqueous extracts of the Chinese medicinal herb Scutellaria barbata,
have been reported to somewhat selectively enhance mitochondr-
ial oxidative stress in cancer cells (58–62). The molecular target(s)
and the basis for the cancer-selectivity of these agents is not yet
clear. Elesclomol’s efficacy appears to hinge on its ability to chelate
copper ions and transport them into mitochondria, where they
potentiate mitochondrial oxidant stress. Since these drugs are not
known to inhibit PDK, they potentially could synergize with DCA
in promoting mitochondrially generated oxidative stress. Indeed,
exposure to DCA, or knock-down of PDK3 with siRNA, has been
shown to potentiate elesclomol’s induction of oxidative stress in
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melanoma cell lines, and concurrent treatment with DCA ampli-
fied the growth retardation of a human melanoma achieved with
elesclomol in nude mice (41). Not surprisingly, elesclomol’s clin-
ical efficacy in melanoma appears to be greater in patients whose
serum LDH levels are not increased; an elevated serum LDH in
melanoma patients is presumed to reflect the presence of cancer
with a high Warburg phenotype, in which mitochondrial respi-
ratory activity is low (63). [LDH is HIF-1 inducible, and hence
its expression is increased in this phenotype (64)]. It would be
interesting to observe the interaction of these strategies with
intravenous ascorbate. The elesclomol–copper complex is capa-
ble of oxidizing ascorbate to generate hydrogen peroxide (65); it
therefore might potentiate ascorbate’s ability to generate hydrogen
peroxide within the extracellular space. Importantly, the reduced
elesclomol–copper complex does not interact with hydrogen per-
oxide to generate hydroxyl radical, so it may be safe for use with i.v.
ascorbate (65). Menadione, which likewise can catalyze the trans-
fer of electrons from ascorbate to oxygen, potentiates the efficacy
of ascorbate therapy in rodent cancer models, without notable
adverse effects (66, 67).
LABILE IRON POOL AS A DETERMINANT OF RESPONSE TO
INTRAVENOUS ASCORBATE THERAPY
The Haber–Weiss reaction requires not only superoxide and
hydrogen peroxide, but also free labile iron or copper. The labile
iron pool (LIP) of cancer cells may therefore be another determi-
nant of a cancer’s sensitivity to intravenous ascorbate therapy; this
is consistent with a report that an intracellular but not extracellular
iron chelator alleviates the toxicity of high extracellular ascorbate
to cancer cell lines (6). It has been proposed that the selec-
tive susceptibility of many cancers to the cytotoxic effects of the
anti-malarial drugs artemisinin or dihydroartemisinin may reflect
increased amounts of free labile iron in those cancers, which inter-
act with artemisinin to generate toxic radicals (68–70). Although
relatively few studies have compared LIP levels in cancers and
healthy tissues, one recent study found that LIP was consistently
higher in breast cancer cells lines than in non-transformed breast
epithelial cell lines (71). Iron deficiency or chelation tends to slow
cancer growth (72–74). Conversely, genetic expression patterns
that predict efficient iron uptake (high transferrin receptor, low
hereditary hemochromatosis), and low capacity for iron export
(low transportin, high hepcidin) are associated with greater risk
of recurrence and decreased survival in breast cancer patients (71,
75). Elevated c-Myc activity, a driver of transformation in many
cancers, tends to increase the LIP by promoting transcription of
the transferrin receptor and IRP2, while suppressing transcription
of the ferritin heavy chain (FHC) (76–79). HIF-1 activity is consti-
tutively active in many aggressive cancers, and is typically elevated
in hypoxic tumor regions (80, 81); since HIF-1 promotes tran-
scription of the gene coding for the transferrin receptor, it would
be expected to increase the intracellular iron pool (82–85). This
predicts that LIP should be relatively high in many aggressive can-
cers. Moreover, the fact that ample iron availability supports rapid
cancer growth and spread, suggests that cancer variants with high
LIP will tend to be selected for as cancers progress. Hence, there is
reason to suspect that LIP is elevated in many cancers, particularly
those that are advanced and aggressive.
INHIBITING NF-KAPPAB ACTIVITY WITH SALICYLATE MAY
INCREASE THE LIP IN CANCERS
On the other hand, too high an LIP can subject cancers to cytotoxic
levels of oxidative stress. The constitutive activation of NF-kappaB
characteristic of many cancers provides protection in this regard.
NF-kappaB promotes transcription of the gene for FHC, counter-
acting the influence of c-Myc in this regard (86–88). FHC is not
only crucial for iron sequestration, but also possesses a ferroxidase
activity that converts toxic Fe+2 to more benign Fe+3, contribut-
ing importantly to antioxidant protection (89). Hence, measures
which inhibit constitutive NF-kappaB activity in cancers tend to
increase the LIP and promote oxidative stress, as has been reported
(87, 88). In contrast, the absence of constitutive NF-kappaB activ-
ity in healthy cells implies that NF-kappaB inhibitors will have
little impact on their FHC levels, which tend to be adequate since
c-Myc is not over-expressed.
Although many chemical agents have been developed capable
of suppressing NF-kappaB activation, the one which is clinically
available is the naturally occurring agent salicylate (also available
as salsalate, a better-tolerated dimer of salicylate that functions
as a pro-drug). Salicylate down-regulates NF-kappaB activity in
cancers by inhibiting IkappaB kinase-beta, a central mediator
of NF-kappaB activation (90, 91). A recent report that dihy-
droartemisinin and salicylate have a complementary impact on
killing of Molt-4 leukemia cells, likely reflects the fact that sal-
icylate, via inhibition of NF-kappaB activity, decreases ferritin
expression and hence increases the LIP, sensitizing the cells to
killing by the dihydroartemisinin (92). [Up-regulation of the
apoptotic response to dihydroartemisinin, and retention of this
drug in cancer cells owing to decreased expression of the mul-
tidrug resistance protein, are additional possibilities in this regard
(91, 93)]. Other factors being equal, it is reasonable to predict that
pre-administration of salicylate, by increasing the LIP in cancer
cells, would also sensitize cancer to destruction by intravenous
ascorbate therapy. This drug, as well as its pro-drug salsalate, has
been used for decades in the treatment of rheumatoid arthritis.
These agents do not produce the gastrointestinal bleeding or renal
damage seen with NSAIDS (as their impact on cyclooxygenase
activity is very mild and transient); their dose-limiting side effect
is ototoxicity, which is fully and rapidly reversible (94–96).
Another approach to increasing LIP in cancer cells prior to i.v.
ascorbate therapy would be to iron load, orally or via intravenous
iron administration. This would be expected to have a somewhat
selective impact on the LIP of the many cancers in which the trans-
ferrin receptor is highly expressed. High oral daily doses of ferrous
sulfate were reported to enhance the sensitivity of a rat fibrosar-
coma to concurrent treatment with dihydroartemisinin; in vitro,
concurrent exposure to holotransferrin boosted the sensitivity of
breast cancer cells to this drug (97, 98). Clinically, intravenous
administration of iron might prove to be a quicker and better-
tolerated strategy for achieving an acute increase in the LIP in
cancers (99).
POTENTIATING THE LETHALITY OF HYDROXYL RADICALS
WITH PARP INHIBITION
Since generation of hydroxyl radicals in the microvicinity of DNA
gives rise to many types of DNA damage (100, 101), it stands
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to reason that tolerable concurrent measures which impede the
efficiency of DNA repair should potentiate the chance that such
damage will prove lethal to the cell. Poly(adenosine diphosphate-
ribose) polymerase (PARP) plays a key role in the repair of single
strand breaks that arise after oxidative damage to DNA (102), and
clinical PARP inhibitors are currently being evaluated clinically in
cancer, either used alone or in conjunction with cytotoxic thera-
pies; these drugs are reasonably well tolerated in doses that can
suppress PARP activity in vivo (103, 104). Ma and colleagues have
recently reported that concurrent exposure of an ovarian cancer
cell line to the PARP inhibitor olaparib (20µM, 24 h) markedly
potentiated the cell kill achieved with ascorbate (2.5 mM, 24 h);
whereas, about 60% of the cells survived exposure to ascorbate
alone, only about 15% of the cells survived ascorbate plus ola-
parib (105). Hence, PARP inhibitors may have important potential
as adjuvants to i.v. ascorbate therapy. This finding also suggests
that nuclear generation of hydroxyl radical is a mediator of the
cytotoxicity of extracellular ascorbate to cancer cells.
Ironically, it is still unclear whether PARP inhibitors will achieve
FDA approval, as the survival benefits and safety of these drugs in
recent clinical studies have not been clear cut (106–110). This may
reflect the fact that PARP inhibitors can potentiate the damaging
impact of cytotoxic chemotherapy on normal tissues, and, when
used alone, spontaneous damage to tumor DNA may be too mod-
est for these agents to achieve an important impact (except pos-
sibly in patients carrying germline mutations in BRCA proteins,
required for repair of DNA double-strand breaks). In contrast,
since severe oxidative stress during i.v. ascorbate therapy appears
to be confined to the cancer, PARP inhibitors may prove to be
quite safe for use in conjunction with such therapy. Hence, once
the capacity of i.v. ascorbate therapy to generate hydroxyl radi-
cals selectively in cancers has been optimized, concurrent PARP
inhibition may have important potential for safely enhancing its
efficacy.
IN OVERVIEW
Figure 1 provides a summary of some of the facts and strategies
cited above.
The fact that a high proportion of cancers generate increased
amounts of superoxide, largely via somewhat dysfunctional mito-
chondria and/or active NADPH oxidase complexes, provides a
straightforward and satisfying rationale for the fact that cancer
cells are selectively susceptible to killing by hydrogen peroxide and
millimolar concentrations of ascorbate; metal-catalyzed interac-
tion of tumor-produced superoxide with the hydrogen peroxide
generated extracellularly by high levels of ascorbate will generate
hydroxyl radicals within the cell. It follows that i.v. ascorbate ther-
apy should be more effective if adjuvant strategies are concurrently
employed that boost superoxide production somewhat selectively
in cancers. One approach to achieve this is to provide additional
substrate for mitochondrial oxidation. In the high proportion of
cancers that express the Warburg effect – reflecting in part con-
stitutive activation of HIF-1 – inhibition of HIF-1-inducible PDK
with DCA increases mitochondrial oxidation of pyruvate. Alterna-
tively, the elevations of free fatty acids and ketone bodies associated
with ketotic diets – coupled with a modest reduction in the glucose
needed for glycolytic ATP generation – could also be expected to
O2
- + Fe+3 → Fe+2 + O2
Fe+2 + H2O2 → Fe
+3 + HO. + HO-
Net Reaction:
O2
- + Fe+3 + H2O2 → HO
. + HO- + Fe+3 + O2
Extracellular ascorbate 
HIF-1 and c-Myc activity; iron loading; 
suppression of ferritin expression via NF-kappaB
inhibition (salsalate)
Dysfunctional mitochondria; NADPH oxidase activity; 
dichloroacetate; ketogenic diet; elesclomol;
hyperthermia
FIGURE 1 | Postulated role of the Haber–Weiss reaction in mediating
the toxicity of high extracellular ascorbate to cancer cells, with
strategies for potentiating this reaction.
boost mitochondrial respiration in cancer cells. Measures which
target HIF-1 expression, such as salsalate and mTORC1 inhibitors,
should also boost mitochondrial respiration while suppressing the
antioxidant effects of cancer glucose metabolism. Hyperthermia
near 42°C promotes oxidative stress in cancer cells – most likely
by boosting mitochondrial superoxide generation – and several
studies show that hydrogen peroxide and hyperthermia can syn-
ergize to kill cancer cells. The copper-transporting investigational
drug elesclomol promotes oxidative stress in mitochondria – pre-
sumably by copper catalysis – and this effect is amplified by the
increased mitochondrial respiration provoked by DCA in cancers
with the Warburg phenotype. The interaction of elesclomol with
exogenous hydrogen peroxide in cancers has not yet been studied,
but should be. Like menadione, elesclomol may potentiate ascor-
bate’s ability to generate extracellular hydrogen peroxide. Tumor
hypoxia renders cancer cells more difficult to kill with ascorbate
than are well-aerated cancer cells in culture; HIF-1 activation
as well as a decrease in oxygen availability for interaction with
ascorbate play a role in this. Measures which increase tumor respi-
ration will have the countervailing negative effect of potentiating
tumor hypoxia; hence, concurrent tumor oxygenation using per-
fluorochemical oxygen carriers or hyperbaric oxygen may improve
responses to i.v. ascorbate therapy. Increasing the cancer pool of
labile iron by antagonizing NF-kappaB activity with salicylate, and
by intravenous iron administration, are additional strategies that
might potentiate the efficacy of i.v. ascorbate therapy of cancer.
And concurrent administration of PARP inhibitors has potential
for amplifying the lethality of oxidant-induced DNA damage.
Despite encouraging anecdotal reports and promising results
in xenograft models (5, 6, 111, 112), the initial formal phase I clin-
ical trials of intravenous high-dose ascorbate therapy for cancer
have so far yielded little evidence of objective response (2, 113).
The possibility that ascorbate therapy can improve the response
to concurrent chemotherapies, as suggested in rodent studies, is
now under active investigation (6, 105, 114, 115). If i.v. ascorbate
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therapy per se is to evolve into an important tool for cancer control,
it appears that adjuvant strategies that complement its impact on
oxidative stress will be required. Complex strategies, which com-
bine several of the therapeutic options cited above in a robust
“oxidative stress therapy of cancer” (116, 117) may have impor-
tant potential for cancer control, and could be evaluated first in
xenograft models.
The mechanistic speculations offered here are based largely on
the results of cell culture studies, which may limit their pertinence
to the impact of high-dose ascorbate in vivo. Nonetheless, the util-
ity of parenteral ascorbate has been well documented in rodent
tumor models.
It should also be noted that measures which notably enhance
intracellular ascorbate levels in cancers – such as correction of
overt vitamin C deficiency, or parenteral administration of dehy-
droascorbic acid – have the potential to slow tumor growth and
boost chemosensitivity by promoting proteasomal degradation of
hypoxia factor-1, a mediator of aggressive growth and chemore-
sistance in many cancers (23, 118–121). This phenomenon would
not be expected to induce the cancer cell death seen when cancer
cells are exposed to high extracellular concentrations of vitamin
C. However, if parenteral ascorbate can increase the intracellu-
lar ascorbate levels of tumors in normally nourished mice – an
issue which requires clarification – this effect might contribute to
the retardation of cancer growth observed in rodent studies with
parenteral ascorbate. The failure of oral vitamin C to control the
growth of advanced cancers in controlled clinical trials may reflect
the facts that such a regimen can only modestly and transiently
enhance plasma levels of ascorbate, and that plasma levels of ascor-
bate in reasonably well nourished subjects are sufficient to saturate
the activity of membrane ascorbate transporters (121, 122).
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